Esomeprazole + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Chronic Posterior Laryngitis (CPL)
Conditions
Chronic Posterior Laryngitis (CPL)
Trial Timeline
Feb 1, 2002 → Mar 1, 2003
NCT ID
NCT00628667About Esomeprazole + Placebo
Esomeprazole + Placebo is a approved stage product being developed by AstraZeneca for Chronic Posterior Laryngitis (CPL). The current trial status is completed. This product is registered under clinical trial identifier NCT00628667. Target conditions include Chronic Posterior Laryngitis (CPL).
What happened to similar drugs?
20 of 20 similar drugs in Chronic Posterior Laryngitis (CPL) were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01069939 | Phase 3 | Completed |
| NCT00660660 | Approved | Completed |
| NCT00542789 | Phase 3 | Completed |
| NCT00287339 | Approved | Completed |
| NCT00745849 | Pre-clinical | Completed |
| NCT00628953 | Phase 2 | Completed |
| NCT00628667 | Approved | Completed |
Competing Products
20 competing products in Chronic Posterior Laryngitis (CPL)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levofloxacin 500 | Dr. Reddy's Laboratories | Pre-clinical | 23 |
| mRNA-0184 | Moderna | Phase 1 | 0 |
| Lubiprostone + Lubiprostone + Placebo | Dr. Reddy's Laboratories | Phase 3 | 37 |
| macitentan 10 mg | BML, Inc. | Phase 3 | 32 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 36 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 23 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 35 |
| THB001 | Third Harmonic Bio | Phase 1 | 11 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 26 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 14 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 29 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 40 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 29 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 44 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 35 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 42 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 21 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 27 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 25 |